Gedea’s ambition is to develop the first antibiotic-free treatment that both prevents and treats bacterial vaginosis. pHyph is a vaginal tablet that has been shown to have an excellent medical effect.
pHyph is developed by Gedea Biotech – a company that was set up by a multidisciplinary team from Lund University.
MEDICAL NEED
Bacterial vaginosis is a recurring problem that affects women around the world.
CLINICAL TRIALS
In our most recently concluded trial, 82% of the subjects were clinically cured of bacterial vaginosis after one week.
1. Socialstyrelsen’s (the Swedish National Board of Health and Welfare) pharmaceutical database 2019.
NEWS
Progress in the clinical trial for bacterial vaginosis
First patient enrolled in Gedea Biotech’s NEFERTITI Clinical Trial of pHyph for antibiotic-free treatment of women with bacterial vaginosis
Gedea on Top 21 list
Gedea’s pHyph antibiotic-free treatment shows high cure rate and low risk of recurrence in bacterial vaginosis in published study
Gedea Biotech receives MHRA approval to initiate NEFERTITI Clinical Trial in the UK of pHyph for antibiotic-free treatment of women with bacterial vaginosis
Gedea Biotech gains ISO 13485: 2016 certification in preparation for CE marking and launch of antibiotic-free bacterial vaginosis treatment
Gedea Biotech is working to reflect the progress being made in healthcare towards a more sustainable future. We are doing this partly by developing a treatment that is safe to use and which complies with all scientific processes and regulations. The fact that pHyph is free from antibiotics also plays an important role in the future treatment of bacterial vaginosis.
